BOTHELL, Wash., Oct. 20 /PRNewswire-FirstCall/ -- Epoch Biosciences, Inc. , a provider of proprietary products that accelerate genomic analysis, announced that third quarter financial results will be released Tuesday, October 26, 2004, prior to market opening. Dr. William G. Gerber, chief executive officer, will host a conference call at 11:00 am ET (8:00 am PT) to discuss the Company's results.
To access the call by telephone, domestic callers dial 800-922-0755 and international callers dial 973-409-9259. An audio replay will be available for 7 days: domestic callers dial 877-519-4471 international callers dial 973-341- 3080 (Passcode # 5304731).
A live webcast of the call may be accessed through the Investor Relations section of the company's website at http://www.epochbio.com/ or directly at http://www.viavid.net/detailpage.aspx?sid=00001FAA. A replay of the call will be available for 45 days.
About Epoch Biosciences
Epoch Biosciences, Inc. develops and sells proprietary products with commercial applications in the genomics and molecular diagnostics fields. Epoch's technology has numerous applications including the detection of inherited diseases, single nucleotide polymorphisms (SNPs) to identify individuals at risk for disease or adverse drug reactions, and gene expression measurement. The company's chemical reagents enhance the performance of genetic analysis procedures, and are compatible with the majority of DNA analysis systems currently employed or under development for research and diagnostic use. The company has an established presence in the research market through licenses to leading genomics companies, global distribution agreements and direct sales to end-users. Epoch also participates in the industrial genomic sector and has entered the diagnostics market. Epoch recently announced the signing of a definitive agreement to merge with Nanogen, Inc. , a San Diego-based developer of advanced in vitro diagnostic products. Information about Epoch is available at http://www.epochbio.com/.
Epoch Biosciences, Inc.
CONTACT: Bert W. Hogue, Chief Financial Officer, Epoch Biosciences,Inc., +1-425-482-5555; or Investor Relations - Jonathan Fassberg or BrianKorb, both of The Trout Group, +1-212-477-9007, for Epoch Biosciences, Inc.